Latest news with #AKRO
Yahoo
22-05-2025
- Business
- Yahoo
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other stocks that skyrocketed today. Ten companies boasted whopping gains on Tuesday despite a wider market pessimism, as a flurry of corporate developments, including impressive earnings and bullish outlooks, sparked buying appetite. In contrast, Wall Street's main indices all finished in the red territory. The Dow Jones was down by 0.27 percent, the S&P 500 dropped 0.39 percent, and the tech-heavy Nasdaq declined 0.38 percent. In this article, we named the 10 best-performing stocks during the trading session and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A scientist in a lab coat examining a sample under a microscope in a laboratory. Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news that it was exploring a sale. According to a report by StreetInsider, Akero Therapeutics, Inc. (NASDAQ:AKRO) is now in talks with an investment bank to assist with the process. However, it added that the company's early interest and strategic review might not necessarily translate to a sale. In its latest earnings release, Akero Therapeutics, Inc. (NASDAQ:AKRO) widened its net loss by 32.6 percent to $70.7 million from $53.3 million in the same period last year. Operating expenses surged by 34.9 percent to $80.88 million from $59.95 million year-on-year. Net loss per common share was at 90 cents, similar to the same period a year ago. Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Overall, AKRO ranks 10th on our list of today's best-performing stocks. While we acknowledge the potential of AKRO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AKRO and that has 100x upside potential, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other stocks that skyrocketed today. Ten companies boasted whopping gains on Tuesday despite a wider market pessimism, as a flurry of corporate developments, including impressive earnings and bullish outlooks, sparked buying appetite. In contrast, Wall Street's main indices all finished in the red territory. The Dow Jones was down by 0.27 percent, the S&P 500 dropped 0.39 percent, and the tech-heavy Nasdaq declined 0.38 percent. In this article, we named the 10 best-performing stocks during the trading session and detailed the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A scientist in a lab coat examining a sample under a microscope in a laboratory. Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news that it was exploring a sale. According to a report by StreetInsider, Akero Therapeutics, Inc. (NASDAQ:AKRO) is now in talks with an investment bank to assist with the process. However, it added that the company's early interest and strategic review might not necessarily translate to a sale. In its latest earnings release, Akero Therapeutics, Inc. (NASDAQ:AKRO) widened its net loss by 32.6 percent to $70.7 million from $53.3 million in the same period last year. Operating expenses surged by 34.9 percent to $80.88 million from $59.95 million year-on-year. Net loss per common share was at 90 cents, similar to the same period a year ago. Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Overall, AKRO ranks 10th on our list of today's best-performing stocks. While we acknowledge the potential of AKRO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AKRO and that has 100x upside potential, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
11-05-2025
- Business
- Business Insider
Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
Akero Therapeutics (AKRO) announced results from new analyses of the 96-week Phase 2b HARMONY trial of efruxifermin, EFX, in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, MASH, in an oral presentation and a poster presentation at the European Association for the Study of the Liver, EASL, Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. The presentations corroborate the antifibrotic activity previously reported by conventional pathology for EFX in patients with pre-cirrhotic MASH. Specifically, among patients treated with EFX, digital pathology analysis by HistoIndex's AI-based qFibrosis showed concordance at the individual level with two non-invasive tests of liver fibrosis-ELF test score and liver stiffness measurement-with more than half of patients treated with 50mg EFX classified as responders by all three endpoints compared to fewer than 5% of placebo patients. Protect Your Portfolio Against Market Uncertainty
Associated Press
24-03-2025
- Business
- Associated Press
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting You can also contact Joshua Grabar at [email protected] or call 267-507-6085. WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose to the investing public that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics. WHAT YOU CAN DO NOW: Current Akero shareholders who have held Akero shares since on or before September 13, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, please visit contact Joshua Grabar at [email protected] or call us at 267-507-6085. $AKRO #Akero Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss: A securities fraud class action complaint against Driven Brands Holdings, Inc. (NASDAQ: DRVN) has survived defendants, attempts to dismiss the complaint. Grabar Law Office is now investigating claims on behalf of long-term Driven Brands shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company. If you have held Driven Brands (NASDAQ: DRVN) shares continuously since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more. WHY: An underlying securities fraud class action complaint alleges that Driven Brands, through certain of its officers and directors, made numerous materially false and misleading statements and omissions pertaining to: (i) Driven Brands' ability to efficiently and effectively integrate a high volume of acquired businesses, including statements related to the status of integrating its U.S. auto glass businesses; and (ii) the performance and competitive position of Driven Brands' car wash business segment. On February 20, 2025, a Federal Court determined that the allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT TO DO NOW: If you are a current Driven Brands shareholder who has held Driven Brands shares since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged to visit contact Joshua H. Grabar at [email protected] or call 267-507-6085. $DRVN #DrivenBrands Integra LifeSciences Holdings Corp. (NASDAQ: IART): Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: Contact Joshua H. Grabar at [email protected], or call 267-507-6085. WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a 'recall' of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off. WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. If you would like to learn more about this matter, you are encouraged to visit contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. $IART #IntegraLifeSciences Kyverna Therapeutics, Inc. (NASDAQ: KYTX): Grabar Law Office is investigating claims on behalf of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shareholders. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you are a current Kyverna (NASDAQ: KYTX) shareholder who purchased Kyverna shares on or near its February 8, 2024 IPO and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit contact Joshua Grabar at [email protected] or call us at 267-507-6085 Why? On February 8, 2024, Kyverna Therapeutics, Inc. (NASDAQ: KYTX) conducted its IPO, offering 14.5 million shares of its common stock to the public at a price of $22 per share for anticipated proceeds of over $296 million. Kyverna granted the Underwriter Defendants a 30-day option to purchase up to an additional 2.175 million shares of its common stock at the Offering Price, less underwriting discounts and commissions. An underlying securities fraud class action complaint alleges that the registration statement and prospectus issued in connection with the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials. The Complaint further alleges that unbeknownst to investors, these representations were materially inaccurate, misleading, and/or incomplete because they did not disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO. What Can You Do Now? If you purchased Kyverna (NASDAQ: KYTX) on or near its February 8, 2024 IPO and still hold shares today, you are encouraged to visit contact Joshua Grabar at [email protected] Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085
Yahoo
27-01-2025
- Business
- Yahoo
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX, helped reverse cirrhosis of the liver in patients with metabolic dysfunction-associated steatohepatitis (MASH). CEO Dr. Andrew Cheng said EFX has "transformational potential" in fighting the of Akero Therapeutics (AKRO) doubled Monday when the pharmaceutical firm that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver disease. The company said a 96-week Phase 2b study of those afflicted with cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) and given a 50mg dosage of its drug efruxifermin (EFX) showed that 39% experienced reversal of cirrhosis with no worsening of MASH. That compares to just 15% of those given placebo. Akero noted that a subgroup of patients who were not on GLP-1 weight-loss medicines, such as Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound, had even better outcomes, indicating that those drugs were not the source of the improvement. Dr. Mazen Nourredin, the principal investigator of the study, said until now, "we've not had the prospect of an effective treatment for compensated cirrhosis due to MASH." Dr. Nourredin added, "Now we have reason to be optimistic about the future potential of EFX as a much-needed treatment for cirrhosis, if approved." CEO Dr. Andrew Cheng explained that EFX has "transformational potential," and the company is continuing evaluation of the treatment in an ongoing Phase 3 trial. Akero Therapeutics shares traded near their all-time high set more than two years ago. Read the original article on Investopedia Sign in to access your portfolio
